Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 19/10/2017
SIETES contiene 92082 citas

 
 
 1 a 20 de 325 siguiente >>
Presentar resultados
Seleccionar todas
2. Cita con resumen
Dimmitt S, Stampfer H, Martin JH. When less is more – Efficacy with less toxicity at the ED50. Br J Clin Pharmacol 2017;83:1365-8. [Ref.ID 101984]
3.Tiene citas relacionadas Cita con resumen
Eunjung Cha A. Monthly shot could be the ‘next revolution’ in HIV therapy, replacing daily pills. The Washington Post 2017:1. [Ref.ID 101921]
4.Enlace a cita originalTiene citas relacionadas Cita con resumen
Feuerstein A. STAT Plus: Strong results for a new HIV drug will be a big boost to Gilead Sciences. STAT 2017:24 de julio. [Ref.ID 101919]
5.Enlace a cita originalTiene citas relacionadas Cita con resumen
Jakobsen JC, Nielsen EE, Feinberg J, Katakam KK, Fobian K, Hauser G, Poropat G, Djurisic S, Weiss KH, Bjelakovic M, Bjelakovic G, Klingenberg SL, Liu JP, Nikolova D, Koretz RL, Gluud C. Direct-acting antivirals for chronic hepatitis C. Cochrane Database of Systematic Reviews 2017;6:6 de junio. [Ref.ID 101674]
6.Tiene citas relacionadas Cita con resumen
Wiktor SZ, Scott JD. What is the impact of treatment for hepatitis C virus infection?. Lancet 2017;390:107-9. [Ref.ID 101668]
7.Tiene citas relacionadas Cita con resumen
Hawkes N. Are new hepatitis C drugs all they’re cracked up to be?. BMJ 2017;357:j2961. [Ref.ID 101659]
8. Cita con resumen
Pease AM, Krumholz HM, Hines HH, Downing NS, Aminawung JA, Shah ND, Ross JS. Postapproval studies of drugs initially approved by the FDA on the basis of limited evidence: systematic review. BMJ 2017;357:j1680. [Ref.ID 101573]
10. Cita con resumen
Anónimo. Combination HCV therapy achieves high sustained viral response. DIA Daily 2016:5. [Ref.ID 100926]
11. Cita con resumen
Anónimo. Ibalizumab shows promising results treating multi-drug-resistant HIV. DIA Daily 2016:4. [Ref.ID 100869]
16.Tiene citas relacionadas Cita con resumen
Davis C, Lexchin J, Jefferson T, Gotzsche P, McKee M. "Adaptive pathways” to drug authorisation: adapting to industry?. BMJ 2016;354:i4437. [Ref.ID 100602]
17. Cita con resumen
Palmer SC, Mavridis D, Nicolucci A, Johnson DW, Tonelli M, Craig JC, Maggo J, Gray V, De Berardis G, Ruospo M, Natale P, Saglimbene V, Badve SB, Cho Y, Nadeau-Fredette A-C, Burke M, Faruque L, Lloyd A, Ahmad N, Liu Y, Tiv S, Wiebe N, Strippoli GFM. Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes. A meta-analysis. JAMA 2016;316:313-24. [Ref.ID 100498]
19. Cita con resumen
Goss PE, Ingle JN, Pritchard KI, Robert NJ, Muss H, Gralow J, Gelmon K, Whelan T, Strasser-Weippi K, Rubin S, Sturtz K, Wolff AC, Winer E, Hudis C, Stopeck A, Beck JT, Kaur JS, Whelan K, Tu D, Parulekar WR. Extending aromatase-inhibitor adjuvant therapy to 10 years. N Engl J Med 2016;375:209-19. [Ref.ID 100399]
Seleccionar todas
 
 1 a 20 de 325 siguiente >>